Related Experiment Video
Updated: Apr 17, 2026
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Negative HER2/neu amplification using immunohistochemistry and chromogenic in situ hybridization techniques in skin
Nasrin Shayanfar1, Leila Bahari, Zahra Safaie-Naraghi
1Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
Background:
This study was performed to evaluate the amplification of HER-2/neu in patients with melanoma.
Materials And Methods:
Amplification of HER-2/neu was evaluated in a group of patients with melanoma, referred to two referral centers in Tehran, using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) techniques.
Results:
Forty patients with mean age 57.9±19.5 years were enrolled in this study. The most frequent type of melanoma was acral, while lower limbs were the most frequent sites. The amplification of HER2/ neu was negative in 97.5% of patients with IHC and in 100% of patients with CISH technique. Only one case (2.5%) shows weak positive staining (+2) in IHC method. Fifty five percent of melanoma was ulcerative, and the most common stages of tumors were stages 4b and 3b. More than 47% of cases were in Clark level III, while the mean of Breslow thickness was 3.56±2.87 mm. The stage of the case that showed weakly positive staining (2+) in IHC was 4b.
Conclusions:
The amplification of HER2/neu biomarker was negative in patients with melanoma, using both CISH and IHC techniques.
More Related Videos
10:21Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
Published on: December 25, 2017
03:55Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens
Published on: July 12, 2024